buthionine sulfoximine has been researched along with colchicine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Parekh, H; Simpkins, H | 1 |
| Kumar, A; Palakurthi, S; Vangara, KK; Yellepeddi, VK | 1 |
4 other study(ies) available for buthionine sulfoximine and colchicine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Survival; Cisplatin; Colchicine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Lymphoma; Methionine Sulfoximine; Mitosis; Ovarian Neoplasms; Paclitaxel; Rats; Tumor Cells, Cultured; Verapamil; Vinca Alkaloids | 1996 |
Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Cell Line, Tumor; CHO Cells; Cisplatin; Colchicine; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Isoflavones; Mass Spectrometry; Ovarian Neoplasms; Sirolimus; Trientine | 2012 |